Vaxart (NASDAQ:VXRT) released its earnings results on Tuesday. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.04, Zacks reports. The business had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.44 million. Vaxart had a negative return on equity of 131.05% and a negative net margin of 244.38%.
Vaxart stock traded down $0.01 during trading on Wednesday, reaching $0.32. 2,458 shares of the company were exchanged, compared to its average volume of 550,066. Vaxart has a 52-week low of $0.25 and a 52-week high of $5.00. The company has a market capitalization of $5.45 million, a P/E ratio of -0.12 and a beta of 0.55. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.29. The stock’s 50 day simple moving average is $0.35 and its two-hundred day simple moving average is $0.60.
VXRT has been the topic of several research reports. HC Wainwright set a $2.00 target price on Vaxart and gave the company a “buy” rating in a research report on Wednesday, August 21st. ValuEngine downgraded Vaxart from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research upgraded Vaxart from a “hold” rating to a “buy” rating and set a $0.25 target price on the stock in a research report on Sunday, November 3rd. Finally, Brookline Capital Management initiated coverage on Vaxart in a research report on Thursday, August 15th. They issued a “buy” rating and a $6.00 target price on the stock.
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.
See Also: Are analyst ratings accurate?
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.